Rachel Owers

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The pure anti-oestrogen fulvestrant has now been licensed for use in advanced breast cancer which has progressed on an anti-oestrogen. Optimal sequencing of various endocrine agents becomes very important in the therapeutic strategy. We report our experience of further endocrine response with another endocrine agent after prior fulvestrant treatment. Among(More)
  • Rachel Owers
  • European journal of oncology nursing : the…
  • 2004
Following the recent approval of fulvestrant ('Faslodex', 250 mg/month) for the treatment of postmenopausal women with advanced or metastatic breast cancer in the European Union, its use in the clinic will increase. The breast cancer nurse specialist and/or the oncology nurse will be the health care professional who administers fulvestrant to patients, and(More)
  • 1